-
SMMT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Summit Therapeutics (SMMT)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 105.19 mm | 105.19 mm | 105.19 mm | 105.19 mm | 105.19 mm | 105.19 mm |
Cash burn (monthly) | (no burn) | (no burn) | 21.87 mm | 18.83 mm | 16.22 mm | 11.84 mm |
Cash used (since last report) | n/a | n/a | 62.87 mm | 54.13 mm | 46.63 mm | 34.04 mm |
Cash remaining | n/a | n/a | 42.32 mm | 51.05 mm | 58.55 mm | 71.15 mm |
Runway (months of cash) | n/a | n/a | 1.9 | 2.7 | 3.6 | 6.0 |
13F holders | Current |
---|---|
Total holders | 205 |
Opened positions | 67 |
Closed positions | 30 |
Increased positions | 75 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 1.52 tn |
Total shares | 117.39 mm |
Total puts | 2.54 mm |
Total calls | 1.66 mm |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Zanganeh Maky | 24.89 mm | $37.83 mm |
Baker Bros. Advisors | 24.42 mm | $435.86 bn |
Vanguard | 11.67 mm | $208.26 bn |
BlackRock | 8.43 mm | $150.46 bn |
FMR | 8.06 mm | $143.75 bn |
T. Rowe Price | 6.56 mm | $117.00 mm |
STT State Street | 5.60 mm | $99.98 bn |
Geode Capital Management | 3.20 mm | $57.13 bn |
Millennium Management | 2.05 mm | $36.58 bn |
Charles Schwab Investment Management | 1.49 mm | $26.50 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jan 25 | Bhaskar Anand | Stock Option Common Stock | Grant | Acquire A | No | No | 17.85 | 75,000 | 1.34 mm | 75,000 |
2 Jan 25 | Robert F. Booth | Stock Option Common Stock | Grant | Acquire A | No | No | 9.18 | 6,855 | 62.93 k | 6,855 |
2 Jan 25 | Robert F. Booth | Stock Option Common Stock | Grant | Acquire A | No | No | 18.35 | 35,000 | 642.25 k | 35,000 |
2 Jan 25 | Alessandra Cesano | Stock Option Common Stock | Grant | Acquire A | No | No | 9.18 | 3,073 | 28.21 k | 3,073 |
2 Jan 25 | Alessandra Cesano | Stock Option Common Stock | Grant | Acquire A | No | No | 18.35 | 35,000 | 642.25 k | 35,000 |
2 Jan 25 | Ronaghi Mostafa | Stock Option Common Stock | Grant | Acquire A | No | No | 18.35 | 35,000 | 642.25 k | 35,000 |
2 Jan 25 | Clark Kenneth A | Stock Option Common Stock | Grant | Acquire A | No | No | 9.18 | 16,991 | 155.98 k | 16,991 |
2 Jan 25 | Clark Kenneth A | Stock Option Common Stock | Grant | Acquire A | No | No | 18.35 | 35,000 | 642.25 k | 35,000 |